PDCD1 and neoplasm: Preclinically, combining adenosine receptor inhibition with either chemotherapy or anti-programmed cell death-1 has resulted in greater tumor control in mouse models, suggesting that AB928 may have synergistic activity when paired with either chemotherapy or checkpoint inhibitors in oncology patients.